吸入型胰岛素
Inhaled insulins.
作者信息
Ghosh Sujoy, Collier Andrew
机构信息
Ayr Hospital, Dalmellington Road, Ayr, Ayrshire, UK.
出版信息
Postgrad Med J. 2007 Mar;83(977):178-81. doi: 10.1136/pgmj.2006.053868.
As a result of knowledge gained from the management of asthma with inhalers and nebulisers, pulmonary delivery devices for insulin have been developed. Particle size of the aerosol particularly influences drug delivery. Although several pharmaceutical companies are developing different systems, Pfizer have launched the first inhaled insulin (Exubera). Clinical trials have taken place in patients with both type 1 and type 2 diabetes, but have shown similar glucose control as subcutaneous insulin delivery. However, patient satisfaction does seem to be increased in patients taking inhaled insulins. Further studies are needed to investigate compliance, side-effect profiles, quality of life, long-term glycaemia control and cost effectiveness.
由于从使用吸入器和雾化器治疗哮喘中获得的知识，胰岛素肺部给药装置得以研发。气雾剂的颗粒大小对药物递送有特别影响。尽管多家制药公司正在研发不同的系统，但辉瑞已推出首款吸入式胰岛素（Exubera）。1型和2型糖尿病患者均已进行临床试验，结果显示其血糖控制效果与皮下注射胰岛素相似。然而，吸入胰岛素治疗的患者满意度似乎有所提高。还需要进一步研究来调查依从性、副作用情况、生活质量、长期血糖控制以及成本效益。
Zotero 插件